

## BAB 5

### SIMPULAN

#### 5.1. Simpulan

Menurut data penelitian yang telah diinterpretasikan, dapat ditarik kesimpulan bahwa dari hasil uji *floating lag time*, matriks carbomer 980 dapat mempengaruhi lama mengapung-mengembang tablet ranitidin HCl dan pada uji pelepasan obat menunjukkan bahwa perbedaan konsentrasi matriks carbomer 980 dapat menghambat pelepasan obat ranitidin HCl. Hal ini dilihat dari profil disolusi yang didapatkan.

#### 5.2. Alur Penelitian Selanjutnya

Dapat dilakukan penelitian lebih lanjut, meliputi:

1. Penelitian yang sama dengan pengamatan terhadap % *Efficiency Dissolution* selama 24 jam.
2. Penelitian dengan menggunakan kombinasi matriks.
3. Penelitian dengan menggunakan metode *non-effervescent* dengan bahan obat yang sama.

## DAFTAR PUSTAKA

- Anonim, 2003, **Gastro-retentive Drugs; A Review**, 1-3  
<http://www.expresspharmapulse.com> (diakses 15 Oktober 2009).
- Anonim, 2010, **Ranitidine - ranitidine hydrochloride**, 1-8  
<http://dailymed.nlm.nih.gov> (diakses 29 Desember 2010).
- Ansel, H. C., 1989. **Pengantar Bentuk Sediaan Farmasi**, Ed. 4. Universitas indonesia, Jakarta, 244-298.
- Banakar, U. V., 1992. **Pharmaceutical Dissolution Testing**, Marcel Dekker, Inc., New york, 2; 19-23; 332.
- Banker, G. S., and Andeerson, N. R., 1994. Tablet, in: **Teori dan Praktek Farmasi Industri**, Lachman, L., Lieberman, H.A. Kanig, J.L. (eds), 3<sup>rd</sup> edition, terjemahan Suyatmi S, Universitas Indonesia, Jakarta, 643-731.
- Chawla, G., Gupta, P., Koradadia, V., Bansal, A. K., 2003, **Gastrorretention: A Means to Address Regional Variability Intestinal Drug Absorbtion**, Pharmaceutical technology, London, 50-60.
- Collet, A., Higgs, N. B., Sims, E., Rowland, M., Warhurst, G., 1999. Modulation of the Permeability of H<sub>2</sub> Receptor Antagonists Cimetidine and Ranitidine by P-Glycoprotein in Rat Intestine and the Human Colonic Cell Line CaCo<sub>2</sub>. **The Journal of Pharmacology and Experimental Therapeutics**, 288(1), 171-178.

Dave, B.S., Amin, A.F., Pattel, M.M., 2004. Gastroretentive Drug Delivery System of Ranitidine Hydrochloride: Formulation and In Vitro Evaluation, **AAPS PharmSciTech**, 5(2), 5.

Devvissaquet, J., and Aiche, J.M., 1982. Sediaan Oral dengan Ketersediaan Hayati Terkendali, In: **Galenica 2-Biopharmacie**, 2<sup>nd</sup> edition, terjemahan DR. Widji Soeratri, Airlangga University Press, Surabaya, 351-352.

Emami, J., *et al*, 2004. Formulation of Sustained-release Lithium Carbonate Matrix Tablets: Influence of Hydrophilic Materials on the Release Rate and in Vitro-in Vivo Evaluation. **J Pharm Pharmaceutical SCL**, 7(3), 338-344.

**Farmakope Indonesia III**, 1979. Departemen Kesehatan Republik Indonesia, Jakarta, 6; 338; 591.

**Farmakope Indonesia IV**, 1995. Departemen Kesehatan Republik Indonesia, Jakarta, 515; 1086.

Garg, D. C., Eshelman, F. N., Weidler, D. J., 1985. Pharmacokinetics of Ranitidine Following Oral Administration With Ascending Doses and with Multiple-fixed Doses. **The Journal of Clinical Pharmacology**, 25(6), 437-443.

Gennaro, A. R., *et al*, 1990. **Remington's Pharmaceutical Science**, 18<sup>th</sup> edition, Mack Publishing Company, Philadelphia, 781-782; 867-868.

Gordon, R. E., Ronsanske, T. W., Fonner, D. E., Anderson, N. R., Banker, G. B., 1990. Granulation Technology, in: **Pharmaceutical Dosage Forms: Tablets**, Vol. 3, 2<sup>nd</sup> edition, Lachman, L., Lieberman, H. A., Marcell Dekker, Inc., New York, 254-268.

Green, J. M., 1996. **A Practical Guide to Analysis Method Validation**, 23; 305-309.

Gunawan, S. G., 2000. **Farmakologi dan Terapi**, 5<sup>th</sup> edition. Departemen Farmakologi dan Terapeutik FKUI, Jakarta, 282-283.

Hosmani, A.H., 2006, **Carbopol and its Pharmaceutical Significance : A Review**, 1-18 <http://www.pharmainfo.net> (diakses 19 November 2009).

Katzung, B. G., 1996. **A Large Medical Book, Base and Clinical Pharmacology**, 5<sup>th</sup> edition, Prentice-hall International Inc., San Fransisco, 296-413; 484-496.

Kortejarvi, H., Yliperttula, M., Dressman, J. B., Junginger, H. E., Midha, K. K., Shah, V. P., Barends, D. M., 2005. Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Ranitidine hydrochloride. **J Pharm Sci**, 94(8), 1617-1625.

Lachman, L., Lieberman, H. A., Kanig, J. L., 1994. The Theory and Practice of Industrial Pharmacy. In: **Teori dan Praktek Farmasi Industri**, 3<sup>rd</sup> edition, terjemahan siti Sutyami, Universitas Indonesia, Jakarta, 934-940.

Lapidus, H., and Lordi, N. G., 1968, Drug Release from Compressed Hydrophilic Matrices. **J. Pharm. Sci.**, 57, 1292-1301.

Lieberman, H. A., Lachman, L., Schwatz, J. B., 1989. **Tablet Formulation and Design, Pharmaceutical Dossage Forms: Tablet**. Vol. 7, 2<sup>nd</sup> edition, Marcell Dekker, Inc., New York, 258-326.

Luer, 2006, **Synthalen K (Carbomer 980)**, 1-2 <http://www.shluer.com> (diakses 19 November 2009).

Martin, A., 1993. Physical Pharmacy. In: **Farmasi Fisik: Dasar-dasar Farmasi Fisik dalam Ilmu Farmasetik**, 3<sup>rd</sup> edition, Martin, A., Swarbrick, J., Cammarata, A., terjemahan Yoshita, Universitas Indonesia, Jakarta, 845; 853-855.

Moffat, A. C., Jackson, J. V., Moss, M. S., Widdop, B., 1986. **Clarke's Isolation and Identification of Drug**, 2<sup>nd</sup> edition, The pharmaceutical Press, London, 533-534.

Parrot, E.L., 1970. **Pharmaceutical Technology: Fundamental Pharmaceutics**, 3<sup>rd</sup> edition, Burgess Publishing Company, Minneapolis, 100-103.

Perez, G. G., Perez, A. G., Lopez, A. T., Olguin, H. J., Perez, C. F., Perez, J. F., Portugal, M. C., Asseff, I. L., And Vieyra, A. C., 2005. Effect of Age on the Pharmacokinetics of Ranitidine in Healthy Mexican Volunteers. **Proc. West. Pharmacol. Soc.**, 48(84-88), 84-88.

Rowe, R. C., Sheskey, P. J., Owen, S. C., 2006. **Handbook of Pharmaceutical Excipients**, 5<sup>th</sup> edition, Pharmaceutical Press, London, 111-113.

Rudnic, E., and Kottke, M., 1996. **Tablet Dosage Forms**. In: **Modern Pharmaceutics**, 3<sup>rd</sup> edition, Marcel Dekker, Inc., New York, 333.

Saifullah, T. N., Syukri, Y., Utami, R., 2007. Profil Pelepasan Propanolol HCl dari Tablet Lepas Lambat dengan Sistem Floating Menggunakan Matriks Methocel K15M. **Majalah Farmasi Indonesia**, 18(1), 48-55.

Siregar, C., 1992. **Manufacture Sediaan Tablet.** Jurusan Farmasi FMIPA Institut Teknologi Bandung, Bandung, 26-45.

Swarbrick, J. (Ed.), 1970. **Current Concepts in Pharmaceutical Sciences Biopharmaceutical Sciences.** The International Copyright Union, Philadelphia, 268-269.

Swarbrick, J. And Boylan, J. C. (Eds.), 1992. **Encyclopedia of Pharmaceutical Technology**, Vol. 5, Marcel Dekker, Inc., New York, 189.

**United States Pharmacopoeia XXIV**, 1999. The United States Pharmacopoeial Convention, Inc., Philadelphia, 546-547.

**United States Pharmacopoeia XXVIII**, 2005. The United States Pharmacopoeial Convention, Inc., Rockville, 1896-1899; 2412-2415.

Wagner, J. G., 1971. **Biopharmaceutics and Relevant Pharmacokinetics**, 1<sup>st</sup> edition. Drug Intelligence Publications, Illinois, 64-110.

Wells, J. I., 1993. **Pharmaceutical Preformulation: The Physicochemical Properties of Drug Substance.** Ellis Horwood Limited, London, 209-214.

Winek, C. L., Wahba, W. W., Winek jr, C. L., Balzer, B. S., 2001. **Drug and Chemical Blood-Level Data.** Fisher Health Care, Pittsburgh, 1-17.